VF
ENTA icon

Virtu Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Virtu Financial’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,967
Closed -$220K – 1809
2025
Q4 		$220K Buy
+13,967
New +$177K 0.01% 980
2025
Q3 		– Sell
-31,533
Closed -$238K – 1629
2025
Q2 		$238K Buy
+31,533
New +$190K 0.01% 850
2024
Q2 		– Sell
-10,927
Closed -$191K – 1454
2024
Q1 		$191K Buy
+10,927
New +$145K 0.01% 803
2019
Q2 		– Sell
-2,702
Closed -$258K – 1563
2019
Q1 		$258K Buy
+2,702
New +$242K 0.01% 858

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Virtu Financial's ENTA Position: Q1 2026 in Review

Virtu Financial sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 13,967 shares — an estimated $220K sold.

Virtu Financial first reported a position in ENTA in Q1 2019 and held it in 4 quarters. The position peaked at $258K in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Virtu Financial reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 13,967 Enanta Pharmaceuticals shares in Q1 2026, an estimated $220K.
  • Virtu Financial first reported a position in Enanta Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Virtu Financial's Enanta Pharmaceuticals position peaked at $258K in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.